GRHL2 Inhibits Colorectal Cancer Progression and Metastasis Via Oppressing Epithelial-mesenchymal Transition

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2019 May 8

PMID 31063022

Citations 20

Authors

Zhou Yang

Dejun Wu

Yusheng Chen

Zhijun Min

Yingjun Quan

Affiliations

Soon will be listed here.

Abstract

Our previous study has demonstrated that knockdown of Grainyhead-like 2(GRHL2) in colorectal cancer (CRC) cells inhibited cell proliferation by targeting ZEB1. This study aimed at researching whether knockdown of GRHL2 promoted CRC progression and metastasis via inducing epithelial-mesenchymal transition (EMT). GRHL2-upregulated SW-620/GRHL2+ and GRHL2-knockdown HCT116/GRHL2-KD, HT29/GRHL2-KD cells and their control cells were generated. The morphological changes after overexpression and knockdown GRHL2 were observed. qRT-PCR, Western blotting, and Immunofluorescence were used to detect EMT markers: E-cadherin, Vimentin, p-catein, ZO-1 and ZEB1 expression. Then, sh-ZEB1 was transfected to GRHL2 knockdown cells to research the relationship between GRHL2 and ZEB1. Transwell and wound healing assays were further performed to detect the impact of GRHL2 on invasion and migration in vitro. CRC cells were injected into mice tail vein to verify the impact of GRHL2 on CRC metastasis. Morphological change of mesenchymal-epithelial transition (MET) could be observed in SW620/GRHL2+ cell. The expression of epithelial markers: E-cadherin, β-catenin, ZO-1 were up-regulated, while mesenchymal markers: Vimentin was decreased. Meanwhile, opposite EMT morphological change could be observed in HCT116/GRHL2-KD cell, accompanied by reverse change of E-cadherin, β-catenin, ZO-1, and Vimentin. The expression level of GRHL2 and ZEB1 was found negative in both SW620/GRHL2+ and HCT116/GRHL2-KD cells. Knockdown of ZEB1 by siRNA in HCT116/GRHL2-KD and HT29/GRHL2-KD could upregulate expression of E-cadherin and GRHL2. GRHL2 knockdown also promoted migration, invasion in vitro and CRC metastasis in mice model. In conclusion, GRHL2/ZEB1 axis inhibits CRC progression and metastasis via oppressing EMT.

Citing Articles

Elevated GRHL2 Imparts Plasticity in ER-Positive Breast Cancer Cells.

Zheng C, Allen K, Liu T, Solodin N, Meyer M, Salem K Cancers (Basel). 2024; 16(16).

PMID: 39199676 PMC: 11353109. DOI: 10.3390/cancers16162906.

In vivo interaction screening reveals liver-derived constraints to metastasis.

Borrelli C, Roberts M, Eletto D, Hussherr M, Fazilaty H, Valenta T Nature. 2024; 632(8024):411-418.

PMID: 39048831 PMC: 11306111. DOI: 10.1038/s41586-024-07715-3.

The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy.

Hsu C, Abdulrahim M, Mustafa M, Omar T, Balto F, Pineda I Med Oncol. 2024; 41(8):202.

PMID: 39008137 DOI: 10.1007/s12032-024-02435-0.

Identification of extracellular matrix-related biomarkers in colon adenocarcinoma by bioinformatics and experimental validation.

Yin Y, Yang X, Cheng Z, Wang H, Lei J, Wang D Front Immunol. 2024; 15:1371584.

PMID: 38694509 PMC: 11061380. DOI: 10.3389/fimmu.2024.1371584.

RBM25 induces trophoblast epithelial-mesenchymal transition and preeclampsia disorder by enhancing the positive feedback loop between Grhl2 and RBM25.

Zhang J, Chen W, Yang K, Wang Z, Sun D, Peng Y Exp Biol Med (Maywood). 2023; 248(14):1267-1277.

PMID: 37728157 PMC: 10621477. DOI: 10.1177/15353702231191199.

References

Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S . A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 2006; 131(3):830-40. DOI: 10.1053/j.gastro.2006.06.016. View

Spaderna S, Schmalhofer O, Hlubek F, Jung A, Kirchner T, Brabletz T . Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh Dtsch Ges Pathol. 2008; 91:21-8. View

Kang X, Chen W, Kim R, Kang M, Park N . Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells. Oncogene. 2008; 28(4):565-74. PMC: 2919678. DOI: 10.1038/onc.2008.404. View

Schmalhofer O, Brabletz S, Brabletz T . E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009; 28(1-2):151-66. DOI: 10.1007/s10555-008-9179-y. View

Nieto M . Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives. Int J Dev Biol. 2009; 53(8-10):1541-7. DOI: 10.1387/ijdb.072410mn. View

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

Werth M, Walentin K, Aue A, Schonheit J, Wuebken A, Pode-Shakked N . The transcription factor grainyhead-like 2 regulates the molecular composition of the epithelial apical junctional complex. Development. 2010; 137(22):3835-45. DOI: 10.1242/dev.055483. View

Zlobec I, Lugli A . Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2011; 1(7):651-61. PMC: 3248128. DOI: 10.18632/oncotarget.199. View

Cieply B, Riley 4th P, Pifer P, Widmeyer J, Addison J, Ivanov A . Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. Cancer Res. 2012; 72(9):2440-53. PMC: 3342427. DOI: 10.1158/0008-5472.CAN-11-4038. View

10.

Pancione M, Remo A, Colantuoni V . Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int. 2012; 2012:509348. PMC: 3409552. DOI: 10.1155/2012/509348. View

11.

Lim J, Thiery J . Epithelial-mesenchymal transitions: insights from development. Development. 2012; 139(19):3471-86. DOI: 10.1242/dev.071209. View

12.

Pieniazek M, Donizy P, Zietek M, Szynglarewicz B, Matkowski R . [The role of TGF-β-related signal transduction pathways in pathogenesis of epithelial-mesenchymal transition as a key element in cancer development and progression]. Postepy Hig Med Dosw (Online). 2012; 66:583-91. DOI: 10.5604/17322693.1009653. View

13.

Morrison C, Parvani J, Schiemann W . The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett. 2013; 341(1):30-40. PMC: 3752409. DOI: 10.1016/j.canlet.2013.02.048. View

14.

Werner S, Frey S, Riethdorf S, Schulze C, Alawi M, Kling L . Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem. 2013; 288(32):22993-3008. PMC: 3743475. DOI: 10.1074/jbc.M113.456293. View

15.

Cieply B, Farris J, Denvir J, Ford H, Frisch S . Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Res. 2013; 73(20):6299-309. PMC: 3806457. DOI: 10.1158/0008-5472.CAN-12-4082. View

16.

Fabian J, Lodrini M, Oehme I, Schier M, Thole T, Hielscher T . GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res. 2014; 74(9):2604-16. DOI: 10.1158/0008-5472.CAN-13-1904. View

17.

Quan Y, Jin R, Huang A, Zhao H, Feng B, Zang L . Downregulation of GRHL2 inhibits the proliferation of colorectal cancer cells by targeting ZEB1. Cancer Biol Ther. 2014; 15(7):878-87. PMC: 4100988. DOI: 10.4161/cbt.28877. View

18.

Quan Y, Xu M, Cui P, Ye M, Zhuang B, Min Z . Grainyhead-like 2 Promotes Tumor Growth and is Associated with Poor Prognosis in Colorectal Cancer. J Cancer. 2015; 6(4):342-50. PMC: 4349874. DOI: 10.7150/jca.10969. View

19.

Klein R, Lin Z, Hopkin A, Gordon W, Tsoi L, Liang Y . GRHL3 binding and enhancers rearrange as epidermal keratinocytes transition between functional states. PLoS Genet. 2017; 13(4):e1006745. PMC: 5425218. DOI: 10.1371/journal.pgen.1006745. View